This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
20 August 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01520-9
References
Shaaban, A. M., Hilton, B., Clements, K., Provenzano, E., Cheung, S., Wallis, M. G. et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. Br. J. Cancer, https://doi.org/10.1038/s41416-020-01152-5 (2020).
Portolani, N., Coniglio, A., Ghidoni, S., Giovanelli, M., Benetti, A., Tiberio, G. A. et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 243, 229–235 (2006).
Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B. et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J. Natl Cancer Inst. 103, 478–488 (2011).
Donker, M., Litiere, S., Werutsky, G., Julien, J. P., Fentiman, I. S., Agresti, R. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J. Clin. Oncol. 31, 4054–4059 (2013).
Warnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J. Clin. Oncol. 32, 3613–3618 (2014).
Wallis, M. G., Clements, K., Kearins, O., Ball, G., Macartney, J. & Lawrence, G. M. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 106, 1611–1617 (2012).
Rakovitch, E., Nofech-Mozes, S., Hanna, W., Narod, S., Thiruchelvam, D., Saskin, R. et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br. J. Cancer 106, 1160–1165 (2012).
Groen, E. J., Hudecek, J., Mulder, L., van Seijen, M., Almekinders, M. M., Alexov, S. et al. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. Breast Cancer Res. Treat. 183, 759–770 (2020).
Thompson, A. M., Clements, K., Cheung, S., Pinder, S. E., Lawrence, G., Sawyer, E. et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. Eur. J. Cancer 101, 210–219 (2018).
Rudloff, U., Jacks, L. M., Goldberg, J. I., Wynveen, C. A., Brogi, E., Patil, S. et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J. Clin. Oncol. 28, 3762–3769 (2010).
Van Bockstal, M. R., Agahozo, M. C., Koppert, L. B. & van Deurzen, C. H. M. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int. J. Cancer 146, 1189–1197 (2020).
Acknowledgements
Not applicable.
Author information
Authors and Affiliations
Contributions
M.R.V.B.: writing—first draft. L.L.: writing—review and editing. C.G.: writing—review and editing.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent to publish
Not applicable.
Data availability
Not applicable.
Competing interests
The authors declare no competing interests.
Funding information
M.R. Van Bockstal received a postdoctoral mandate (grant number 2019-089) from the not-for-profit organisation Foundation against Cancer (Brussels, Belgium), and is supported by the “Fonds dr. Gaëtan Lagneaux” of the Fondation Saint-Luc (Brussels, Belgium). C. Galant is supported by the “Fonds dr. Gaëtan Lagneaux” of the Fondation Saint-Luc (Brussels, Belgium).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: Due to an Additional Information error.
Rights and permissions
About this article
Cite this article
Van Bockstal, M.R., Libbrecht, L. & Galant, C. Comment on: “Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project”. Br J Cancer 124, 1461–1462 (2021). https://doi.org/10.1038/s41416-021-01280-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01280-6